5 Key Takeaways

• 1

  Vuity is the first FDA-approved eye drop for presbyopia, enhancing near vision without significantly affecting distance vision.

• 2

  Qlosi, approved in 2023, offers a lower dose of pilocarpine and similar benefits to Vuity, but is not yet commercially available.

• 3

  LNZ100, a new pupil-selective miotic, has shown promise in phase 3 trials and aims for FDA approval by August 2025.

• 4

  Brimochol PF combines carbachol and brimonidine to improve near vision with fewer side effects, targeting a 2026 launch.

• 5

  Ryzumvi, initially approved for mydriasis reversal, is under investigation for presbyopia treatment in ongoing phase 3 trials.